Organization | HAL Allergy

HAL Allergy Report issue

For profit Phase 1 Phase 2 Phase 4

Founded: Leiden Netherlands (1959)

Status: No NME R&D (1959)

Organization Overview

First Clinical Trial

2006

NCT00422149

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

HAL Allergy

Active Ingredients

Drugs in Phase 4 Trials (2)

birch allergen (4 trials)

timothy grass pollen allergen extract (Grastek) (2 trials)

Drugs in Phase 2 Trials (2)

house dust mite allergen (3 trials)

trifolium pratense (2 trials)

Drugs in Phase 1 Trials (3)

aluminum hydroxide (Gaviscon) (1 trial)

hal-mpe1 (2 trials)

short ragweed pollen allergen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 4)

Hypersensitivity (Phase 1)

Peanut Hypersensitivity (Phase 1)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial APIs: 7